ProfileGDS5678 / 1445004_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 16% 16% 16% 15% 16% 16% 16% 16% 16% 16% 16% 16% 16% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4270216
GSM967853U87-EV human glioblastoma xenograft - Control 22.3944316
GSM967854U87-EV human glioblastoma xenograft - Control 32.3912616
GSM967855U87-EV human glioblastoma xenograft - Control 42.3362716
GSM967856U87-EV human glioblastoma xenograft - Control 52.3344915
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4585116
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4178216
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3688316
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3588416
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3797116
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3755116
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3619616
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3867316
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3799516